

University of Groningen

Gaining insight into the determinants of mortality in hospitalized severely malnourished children

Versloot, Chris

DOI:

[10.33612/diss.193369178](https://doi.org/10.33612/diss.193369178)

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version

Publisher's PDF, also known as Version of record

Publication date:

2022

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):

Versloot, C. (2022). *Gaining insight into the determinants of mortality in hospitalized severely malnourished children: a translational and intestine focused approach*. [Thesis fully internal (DIV), University of Groningen]. University of Groningen. <https://doi.org/10.33612/diss.193369178>

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

CHAPTER 1

General introduction
and thesis outline

Childhood malnutrition is amongst one of the most challenging global health problems. The complexity of childhood malnutrition has intrigued countless health care professionals, scientists and policy makers for decades and many have committed to solve this problem to improve child survival. Unfortunately, childhood malnutrition still threatens the lives and future of far too many young children; malnutrition increases the risk of death, makes children more susceptible to disease and holds them back from reaching their full physical and cognitive potential^{1,2}.

Substantial progress has been made in the therapeutic management and survival of severely malnourished children¹. However, considerable disparities in survival continue to exist between severely malnourished children with and without medical complications. While community-based programmes have transformed outcomes for children with uncomplicated severe malnutrition³, severely malnourished children with complications still face high mortality rates during treatment in hospital. In African hospitals mortality still ranges between 23 and 46%⁴⁻⁷. Even after discharge, the prognosis is poor with reported mortality rates as high as 42% in the subsequent year⁵.

Many severely malnourished children suffer from diarrhoea during hospital admission, which increases their risk of death substantially⁸⁻¹⁰. Studies have revealed that intestinal structure and function are seriously disrupted in severely malnourished children with more severe changes reported in children with concurrent diarrhoea^{11,12}. Accumulating evidence suggests that this enteropathy may persist despite treatment¹³, which could contribute to poor clinical outcomes in hospital. The continuation of diarrhoea and outstandingly high mortality rates during admission, as well as high mortality rates after discharge, suggest that current treatment algorithms may not fully address the changes in the intestine of these severely ill children. Moreover, limited characterization of these potentially persistent intestinal changes and limited insights into their underlying mechanisms hamper our ability to provide the optimal treatment needed for survival and recovery.

This chapter describes the epidemiology, pathophysiology and therapeutic management of severe childhood malnutrition. Next, it discusses the current knowledge of intestinal changes in severe malnutrition, including putative underlying mechanisms. Moreover, it highlights the need for new preclinical models to study the mechanisms underlying intestinal changes in severe malnutrition.

Severe childhood malnutrition

Definition of childhood malnutrition

Malnutrition refers to an imbalance in the intake of nutrients and energy relative to the body's requirements to ensure homeostasis and, in the case of children, optimal growth. Malnutrition can be caused by nutrient deficiencies or excesses, otherwise known as undernutrition and overnutrition¹⁴. In this thesis, the term malnutrition refers to undernutrition in children. The current classification of childhood malnutrition is based on body measurements (e.g. body weight, mid-upper arm circumference) and compares these parameters with a reference population that the World Health Organization (WHO) designated as "healthy growers"¹⁵.

Several forms of childhood malnutrition are recognized: stunting, wasting, underweight and deficiencies of vitamins and minerals. Stunting or reduced linear growth results from chronic or recurrent undernutrition, whereas wasting can indicate more acute severe weight loss. The term 'underweight' encompasses both stunting and wasting. A child is stunted when he or she is too short for their age, which is defined as a height-for-age that is more than two standard deviations below the WHO Child Growth Standards median (HAZ score < -2). Inadequate nutrition, recurrent infections and/or chronic diseases are some of the most direct causes of stunting. Stunting has adverse long-term consequences for survival, child and adult health, and cognitive development^{16,17}. A child is wasted when he or she is too thin for their height, which is defined as a weight-for-height (> 2 years of age) or weight-for-length (< 2 years of age) that is more than two standard deviations below the WHO Child Growth Standards median (WHZ/WFL score < -2).

Definition of severe acute malnutrition and historical perspective

Severe acute malnutrition (SAM), which is the focus of this thesis, is the most life-threatening form of undernutrition. SAM is currently defined as a WHZ score < -3 , mid-upper arm circumference (MUAC) < 11.5 cm and/or bilateral pitting oedema in children between 6-59 months of age^{18,19}. SAM classically presents as one of two phenotypically distinct forms that are marked by different metabolic responses to severe undernutrition: the non-oedematous form known as marasmus, and the oedematous forms, which include kwashiorkor and marasmic-kwashiorkor²⁰. Marasmus is defined by severe wasting of adipose and muscle tissue. A child with marasmus is extremely thin ("skin over bones") and often has a wizened "old man" appearance (**Figure 1**). Oedematous

malnutrition was first described in several local publications in Latin America during the 19th century (cited in ²¹) and was followed by other occasional reports^{22,23}. However, it was only after the report of Dr. Cecily Williams in 1933²⁴ describing this disorder as “a nutritional disease of childhood associated with a maize diet” and giving the condition its present name “Kwashiorkor” in 1935²⁵, that the condition became widely recognized. During the early 1950s, Brock and Autret²⁶ demonstrated that kwashiorkor was prevalent in sub-Saharan countries and provided a clear description of the clinical features that matched the earlier description by Dr Williams²⁴. Subsequent surveys demonstrated that kwashiorkor was also prevalent in Central America²⁷ and Brazil²⁸. In these studies, intermediate cases between kwashiorkor and marasmus were also described (e.g. stunting and hair depigmentation but no oedema). Kwashiorkor was defined as a clinical syndrome, mainly seen in children under the age of 2 years. The clinical characteristics included the presence of bilateral pitting oedema, skin rashes, ulceration (e.g. flaky paint dermatosis) and hair abnormalities (e.g. sparse, depigmented hair) (**Figure 1**). In 1952, the Joint Food and Agriculture Organization (FAO)/WHO Committee on Nutrition introduced the term “protein malnutrition” referring to the concept that kwashiorkor was due to an inadequate dietary protein intake as opposed to marasmus which was the outcome of prolonged insufficient dietary intake of all macronutrients²⁹. In 1960, the FAO/WHO expert committee proposed that kwashiorkor and marasmus were two main categories of ‘protein-calorie malnutrition’, which referred to the observation that diets in these areas are commonly low in protein, but provide calories ranging from inadequate to excessive³⁰. In the years following the introduction of kwashiorkor as a clinical syndrome, some authors also used the term kwashiorkor to describe conditions when only some of the clinical manifestations of kwashiorkor were observed leading to some confusion. In 1970, a consensus was reached on the categorisation of malnutrition; kwashiorkor should be used for children with oedema, marasmus for children with a low weight-for-age (later replaced by weight-for-height³¹) and marasmic-kwashiorkor for children with both oedema and low weight-for-age. The hair, skin and liver manifestations were not included in this definition³². Some scientists started to use the term “oedematous malnutrition” instead of kwashiorkor. In this thesis, the terms severe wasting and oedematous malnutrition will be used to indicate marasmus and (marasmic-)kwashiorkor, respectively.




Figure 1. Severe acute malnutrition. Clinical characteristics of severely malnourished children diagnosed with marasmus/severe wasting (left) and kwashiorkor/oedematous malnutrition (right).

Epidemiology

Childhood malnutrition still affects and threatens the lives of an overwhelming number of children worldwide. Young children under the age of five bear the brunt of the problem being more susceptible due to their high nutritional demands during this period critical for child growth and development. The majority of malnourished children live in low- and middle-income countries; Africa and Asia account for the largest shares of the global burden with 27% and 69% of wasted children respectively¹. In 2019 an estimated 144 million children under the age of five were stunted and 47 million were wasted, of whom 14.3 million children were severely wasted¹. There are no accurate estimates on the global burden of oedematous malnutrition. This dearth of reliable data is due to the large geographical variability of oedematous malnutrition, the fact that assessment of oedema is often not included in large nutritional surveys and the transient nature of this disease (oedema spontaneously resolves or the child dies) which complicates its timely detection in surveys³³. However, estimates from various African countries suggest that oedematous malnutrition accounts for more than a third of severe malnutrition cases; African countries such as Malawi, Rwanda and Zambia are at the top of the list where oedematous malnutrition accounts for 50%, 47.1% and 44.7% of all severe malnutrition cases respectively³⁴. While oedematous malnutrition is apparently prevalent in many African countries, considerably lower numbers are reported in Asia with oedematous malnutrition accounting for less than 15% of all severe malnutrition cases³⁴. The geographical differences in the prevalence of the different forms of severe malnutrition probably indicate that the distribution, causes and consequences of risk factors for malnutrition vary across regions. Risk factors for childhood malnutrition include living in areas with high burdens of infectious diseases (e.g. respiratory tract infections, diarrhoea, HIV), with endemic food insecurity (e.g. famine, suboptimal feeding practices) and with

suboptimal social and environmental conditions (e.g. poverty, limited access to health care, poor education)³⁵.

Severely malnourished children have severely disturbed physiology and metabolism²⁰. To illustrate, hypoglycaemia due to disturbed glucose homeostasis^{36,37} and diarrhoea related to disrupted intestinal homeostasis are common with negative impacts on survival^{9,10,38}. In addition, severely malnourished children are not only more susceptible to infectious diseases, but also face higher disease severity and case fatality^{39,40}. It is not surprising that regions with high numbers of severely malnourished children often also experience high childhood mortality rates, which implies that malnutrition may play an important role in the risk of death. The Lancet Nutrition series in 2013 reported that malnutrition directly or indirectly underlies almost half of all childhood deaths worldwide². Severe malnutrition carries the highest mortality and contributes to approximately half a million deaths in children under five years of age worldwide². Most deaths in severely malnourished children can be linked to infectious diseases such as diarrhoea and malaria and metabolic disturbances such as hypoglycaemia and refeeding syndrome^{41,42}. Altogether, these numbers underline the significant burden of morbidity and mortality in children suffering from severe malnutrition.

Aetiology and pathophysiology

Insight into the predispositions and pathophysiological pathways that lead to wasting has increased over the years, while the aetiology of oedematous malnutrition still remains an enigma.

Wasting

Inadequate protein and energy intake is generally recognized as important contributor to loss of muscle and adipose tissue in wasting, but wasting is seldom caused by a single factor²⁰. Although the onset and resolution of wasting can be relatively quick, the factors that drive wasting are often more longstanding, for example recurrent infectious insults. Risk factors for childhood wasting include maternal factors (e.g. low BMI, educational level), diseases (e.g. infectious disease, diarrhoea) and environmental factors (e.g. seasonality, household wealth)⁴³. Studies have highlighted that interactions between risk factors exist and that some factors can be both a cause and a consequence of wasting. In addition, risk factors are often context-dependent; the significance and impact of particular risk factors can change over time, with the age of the child and with changes in the context (e.g. population displacement, famine). This intricate interplay of risk factors

makes the aetiology of wasting complex.

Our knowledge of the physiological mechanisms and metabolic adaptations that accompany wasting remains limited and is mainly derived from publications on long-term starvation and wasting due to a chronic illness (cachexia)⁴⁴. During short-term starvation (fasting up to several days), the body shifts from carbohydrate metabolism to fat and protein catabolism, which provides glucose and ketones for energy²⁰. After several days of starvation, body fat has been depleted and therefore muscle proteins are extensively broken down. Importantly, evidence suggests that these metabolic disturbances may continue after recovery from the wasting episode, which could increase vulnerability to relapse and also limit the growth potential of affected children⁴³.

Oedematous malnutrition

Research into the divergence of malnutrition phenotypes has led to many hypotheses about the origin of oedematous malnutrition. These hypothesis are extensively reviewed by André Briand⁴⁵ and include: 1) insufficient protein intake, 2) insufficient intake of particular amino acids, 3) maladaptation to a low-protein carbohydrate-rich diet, 4) oxidative stress, 5) intoxication with aflatoxins produced by *Aspergillus* species, 6) disruption of sulphated glycosaminoglycans (GAGs) and more recently, 7) dysbiosis of the microbial community in the gut, referred to as gut microbiota. However, none of these hypotheses can fully explain all clinical and pathophysiological characteristics of oedematous malnutrition. Therefore, considerable interest remains to explain the divergent malnutrition phenotypes. A recent comparative meta-analysis has systematically reported the available information on differences in pathogenic characteristics between children with severe wasting and oedematous malnutrition⁴⁶. This is of importance as children with characteristics of oedematous malnutrition have a poor prognosis and respond differently to treatment compared to children with severe wasting. This may reflect more severe disturbances in organ physiology and metabolism⁴⁵. The known structural and functional impairments of organ systems (e.g. altered immune function, liver dysfunction) in severe malnutrition have been reviewed by Bhutta et al.²⁰. The current understanding of small intestinal changes will be discussed in the section 'malnutrition enteropathy'.

Treatment

Appropriate management of severe malnutrition is critical for child survival. The WHO developed clinical guidelines that take into account the known physiological and metabolic

changes in severely malnourished children^{47,48}. In general, treatment includes correction of nutritional deficiencies with therapeutic food and treatment of underlying infections with antibiotics. A distinction in recommended treatment is made between children with complicated and uncomplicated severe malnutrition. Children who have no medical complications and who are able to feed sufficiently can be managed as outpatients. Children require inpatient treatment if they have medical complications including severe oedema, poor appetite, or when they are presenting with ≥ 1 Integrated Management of Childhood Illness (IMCI) danger signs (convulsions, lethargy, reduced conscious level and inability to feed sufficiently)⁴⁸.

Outpatient management of uncomplicated severe malnutrition is increasingly provided in community-based treatment centres through Outpatient Therapeutic Programs or OTPs. Children receive ready-to-use therapeutic foods (RUTF) in order to achieve adequate weight gain, which is monitored during regular visits to a local health facility. RUTFs are high-energy, fortified, ready-to-eat foods with a similar nutritional content to the F-100 therapeutic milk formula used to treat severely malnourished children. These foods were designed in a dehydrated form to reduce the risk of contamination and to allow safe use at home without preparation⁴⁹. The rapid expansion of community treatment programmes extended the reach of treatment to previously untreated children. The outpatient approach yields good results with adequate weight gain, high recovery (approximately 80%)^{3,50} and relatively low reported mortality rates of $<1-7\%$ ^{50,51}.

Inpatient treatment of children with complicated severe malnutrition aims to treat life-threatening conditions (e.g. infections) and to correct nutritional deficiencies and metabolic disturbances. Recommended nutritional management occurs in three distinct phases with diets that are tailored to match the child's reduced metabolic capacity and to meet the estimated nutritional needs per treatment-stage^{47,48}. In the first phase, the "stabilization phase", therapeutic feeding is cautiously started with a milk-based formula diet called F-75. F-75 contains low levels of protein and sodium and high levels of potassium, which should aid stabilization of physiological and metabolic functions in this stage. Feeding is started cautiously to avoid refeeding syndrome with its associated life-threatening metabolic derangements. Feeding can cause the catabolic state to rapidly switch to an anabolic state, which can lead to insulin secretion, acute hypoglycaemia and the transport of extracellular electrolytes into cells. The flux of electrolytes into cells can cause dangerously low blood concentrations of potassium, magnesium and phosphate. This in turn can lead to impaired cardiac function, respiratory failure, muscle weakness, impaired neurological function (e.g. lethargy, seizures) and sudden death⁵².

The incidence of refeeding syndrome in malnourished children is unknown. When signs of clinical improvements such as regained appetite and, in cases of oedematous malnutrition, reduced oedema are observed, the child enters the second phase, the “transition phase”. In this phase, the child will gradually transition to a diet with higher protein and energy content to achieve weight gain through either F-100 formula or RUTFs started with supplemental F-75 formula until the child is able to finish all the RUTF feeds. Finally, the child enters the last phase, the “rehabilitation phase”, during which their daily intake of F-100 or RUTFs is increased to achieve catch-up growth. Under current WHO recommendations, the child can be discharged from hospital once clinically stable (e.g. serious complications have resolved) and tolerating RUTFs. Therapeutic feeding with RUTFs should be continued as an outpatient with regular follow-up in an outpatient clinic, where RUTFs are supplied and weight gain is monitored. Once discharged from outpatient treatment, the child should ideally be periodically monitored to avoid relapse.

Clinical outcomes for children with complicated severe malnutrition treated in hospital are considerably worse than for children with uncomplicated severe malnutrition treated as outpatients⁴⁻⁷. The factors driving persistent high inpatient mortality rates are not entirely clear. Major risk factors for mortality during inpatient treatment are reportedly diarrhoea, pneumonia, HIV infection, shock, anaemia, hypoglycaemia, MUAC<11.5cm and a low WHZ on admission^{53,54}. These risk factors underscore that comorbidities and decompensation of physiological pathways are common in children with complicated severe malnutrition. WHO compliant management in hospital may reduce mortality to some extent, but the high mortality rates imply that the current management algorithms may be insufficient for treating this vulnerable population. Interestingly, the current WHO treatment guidelines have become engrained in daily clinical practice, even though the scientific basis is sparse, evidence is often “very low quality” and guidelines are mostly based on expert opinion⁵⁵. The dearth of evidence for the treatment regimen is related to our limited understanding of many of the pathophysiological mechanisms underlying comorbidities and metabolic disturbances observed in severely malnourished children.

Severely malnourished children with diarrhoea often fail to respond to the current inpatient treatment regimen and pose one of the most difficult management challenges. Limited histological studies have shown that intestinal architecture is seriously altered^{11,12,56}, which can lead to nutrient malabsorption and intestinal barrier dysfunction in severely malnourished children^{11,57}. More detailed knowledge is required of 1) the disruption in intestinal homeostasis, 2) the effect of treatment on intestinal structure and function, and 3) the mechanisms underlying intestinal alterations in severely malnourished

children. These insights will enable us to better tailor treatment to the intestinal needs; or in other words “design food from the inside out”. In the next section, I will provide an overview of the anatomy and physiology of the small intestine, and then discuss the current understanding of small intestinal changes present in severe malnutrition.

Small intestine in health and in severe malnutrition

Intestinal anatomy

The small intestine is part of the gastrointestinal tract. The gastrointestinal tract is a term comprising all elements of the alimentary canal, stretching from the mouth to the anus, and its accessory organs including the salivary glands, liver and pancreas⁵⁸. The overall function of the gastrointestinal tract is to digest and absorb nutrients from ingested food. In the mouth, salivary and lingual enzymes initiate the digestion of carbohydrates and lipids. The oesophagus serves as a conduit for the transportation of the food bolus to the stomach, where gastric acid and digestive enzymes (e.g. proteases, lipase) break it down further. Next, the bolus reaches the small intestine; this is the principal site of nutrient digestion and absorption and consists of three segments from proximal to distal: duodenum, jejunum and ileum⁵⁸. Secretions from different organs aid in the digestive process here including bile acids from the liver for lipid digestion and pancreatic enzymes such as lipase, chymotrypsin and amylase for digestion of lipids, protein and dipeptidases, respectively. Enzymes on the luminal surface of the small intestine or ‘brush border enzymes’ (e.g. disaccharidases, dipeptidases) complete the digestion of carbohydrates and proteins. Once in the large intestine or the colon, fluids and electrolytes are reabsorbed. The colon is highly colonized by resident bacteria, viruses and fungi referred to as the gut microbiota⁵⁹. Commensal bacteria have important functions such as vitamin B and K production as well as fermentation of carbohydrates that are not used by the host⁵⁹. These non-digestible carbohydrates are converted to short-chain fatty acids (SCFA) (e.g. acetate, butyrate), which are mostly absorbed by the host and serve as a fuel source for epithelial cells⁶⁰. Finally, the luminal content or faeces is expelled from the body.

The structural organization of the alimentary canal is similar throughout its length. It consists of four layers from the lumen outward: mucosa, submucosa, muscularis externa and serosa or adventitia⁵⁸. The mucosa is the innermost layer consisting of the epithelium, the lamina propria and the muscularis mucosae. The submucosa, a connective tissue layer, connects the mucosa with the muscular layer muscularis externa; this is involved

in segmental contractions and peristalsis. The serosa and adventitia cover the external surface of the abdominal organs. The mucosa differs along the tract and is specifically adapted to the function of each specific part. The anatomy and physiology of the small intestinal mucosa, as the principal site of nutrient absorption and digestion, will be explained in more detail below.

Physiology of the small intestinal mucosa

The small intestinal mucosa has a complex task to serve as a semipermeable barrier that allows nutrient absorption, while also forming a defence against harmful substances, pathogens and foreign antigens. Regulation of this seemingly paradoxical task is supported by the structural composition of the intestinal mucosa. The intestinal mucosa consists of the mucus layer on the outside, a central single cell layer with differentiated and specialized epithelial cells, and the inner lamina propria with immune cells⁶¹ (**Figure 2**). The intestinal epithelium and mucus layer will be discussed in this section.




Figure 2. Intestinal mucosa serving as a semipermeable barrier.

Intestinal epithelial cells

The intestinal epithelium, composed of a single cell-layer, is arranged into a large number of crypt-villus units. A villus is a finger-shaped protrusion of the intestinal wall into the lumen and is surrounded by multiple invaginations known as crypts⁶². The intestinal epithelium is the fastest self-renewing tissue in mammals; in mice the epithelium is

completely renewed every 3-5 days, except for Paneth cells which have a life span of 3-6 weeks^{63,64}. The crypt-villus architecture with its rapid turnover rate enables the small intestine to simultaneously serve as both a protective barrier and as the primary site of nutrient absorption. The small intestine owes its great nutrient absorptive capacity to the large surface area provided by its villi and microvilli, protrusion of villi into the lumen and the close relation to a dense network of capillaries underneath the epithelium to transport nutrients to the liver and the rest of the body⁶². However, this sophisticated architecture makes it vulnerable to a variety of assaults including mechanical stress, pathogens and digestive enzymes, all of which can damage the integrity of the epithelium. A continuous layer of intestinal epithelial cells and intercellular junctions are essential to preserve the integrity of the intestinal epithelium.

The layer of epithelial cells is maintained by a high epithelial turnover rate; this also reduces the time that the epithelium is exposed to harmful intraluminal conditions. Rapid epithelial turnover is supported by continuously dividing intestinal stem cells (ISCs) which reside at the base of the crypts where they are shielded from the hazards of the digestive process⁶² (**Figure 3**). ISCs continuously undergo self-renewal and generate rapidly proliferating transit amplifying (TA) cells which differentiate into mature intestinal epithelial cells (IECs). IECs are pushed out of the crypts, migrate upwards the crypt-villus axis (except for Paneth cells), undergo apoptosis and are shed from the villus tip into the intestinal lumen^{65,66}. Mature IECs types fulfil specialized functions and can be divided in absorptive (enterocytes and M cell) and secretory lineages (Paneth, goblet, enteroendocrine and tuft cell)⁶⁵ (**Figure 3**). Enterocytes are the most abundant IEC type, comprising about 80% of the intestinal epithelium, and are responsible for nutrient and water absorption. Goblets cells are specialized secretory cells which maintain a protective mucous layer on top the epithelium through generation and excretion of mucins. Enteroendocrine cells participate in metabolic control by acting as chemoreceptors and producing different hormones (e.g. glucagon-like peptide 1 and 2). Paneth cells reside at the base of the crypts. They play an important role in defence against invading microorganisms via the secretion of antimicrobial peptides such as defensins and lysozyme. In addition, Paneth cells also support ISC maintenance by secreting paracrine factors (e.g. WNT ligands, Notch stimuli)⁶⁷ and providing nutrients to ISCs⁶⁸. Thus, a continuous supply of the different mature IECs in appropriate proportions is required to maintain intestinal homeostasis.

The continuous supply of new epithelial cells to the crypt-villus axis is fuelled by ISCs called crypt base columnar cells (CBCs)⁶⁹ or Lgr5+ cells based on expression of the stem cell marker 'leucine-rich-repeat-containing G-protein-coupled receptor 5 (Lgr5)⁷⁰. Stem

cell dynamics are regulated by various signals which come from the epithelium (e.g. Paneth cells) and from the underlying mesenchyme. Key signals that regulate stem cell renewal and intestinal fate determination (e.g. R-spondin, BMP) are extensively reviewed by Gehart and Clevers⁶². In addition to the capacity to self-renew under homeostatic conditions, the intestine has the ability to regenerate upon damage and survive acute loss of its active stem cell pool. Repopulation of the stem cell niche has been attributed to three mechanisms: mobilization of quiescent 'reserve' stem cells located at the +4 position^{71,72}, de-differentiation of progenitor cells^{73,74} and differentiated absorptive and secretory cells that are able to revert to a stem cell state^{75,76}.




Figure 3. Morphology of the small intestine in healthy children (left) and in malnourished children (right).

Intercellular junction complexes mechanically connect intestinal epithelial cells and seal the intercellular space. These protein networks form three adhesive complexes: tight junctions (TJs), adherens junctions (AJs) and desmosomes (**Figure 4**) (reviewed in ⁷⁷). TJs, which are the most apically located in this complex, are responsible for sealing the intercellular space, whilst AJs and desmosomes are thought to be important in mechanical linkage of adjacent cells. Tight junctions are composed of several transmembrane and cytosolic proteins (e.g. occludin, claudins, zonula occludens (ZO)) and junctional adhesion molecules (JAM), which interact not only with each other but also with the cytoskeleton⁷⁷. Tight junctions, as dynamic structures, have the capacity to maintain barrier integrity and finely regulate paracellular transport. In addition, TJs prevent microbial translocation, maintain epithelial polarity and are involved in the regulation of cell proliferation and migration⁷⁷.




Figure 4. Cell-cell adhesion proteins between intestinal epithelial cells. Tight junctions are most apically located, followed by adherens junctions and desmosomes.

Mucus layer

The mucus layer, covering the IECs, shields them from direct contact with mechanical, biological and chemical hazards (e.g. digestive enzymes, bacteria) and protects the IECs from dehydration⁷⁸. The thickness and structure of the mucus layer varies considerably along the intestinal tract. In the small intestine, the mucus is organised in a single layer that is easily removable and relatively porous. Whilst this enables efficient nutrient absorption, it also enables pathogens to penetrate the mucus⁷⁹. However, the presence of antimicrobial agents in the mucus offers protection against pathogens with the highest concentrations in the crypts, as these components (e.g. defensins, lysozyme) are mainly produced by Paneth cells⁸⁰. In the large intestine, the mucus layer consists of two layers with the inner layer virtually free of bacteria but the outer layer containing gut bacteria and dietary components⁸¹. The mucus layer provides an important niche for the microbial community and can be used by bacteria as binding sites and as an energy source promoting their colonisation and growth⁸².

The major components that give mucus its viscous and elastic properties are large glycoproteins called mucins. Mucins are produced by goblet cells and fall into two main groups: transmembrane mucins or gel-forming mucins. Mucin 2 (MUC2) is the main gel-forming mucin in the intestine⁸³. A number of different factors influence the mucus barrier, ranging from host factors, such as the gut microbiota, cytokines, to external factors such as pathogens, diet, food additives, antibiotics and pre- and probiotics^{82,84–86}. Impairment of the mucus layer can be related to reduced mucus synthesis and secretion,

increased mucus degradation and penetrability, and altered mucus composition (e.g. viscosity)⁸⁴. Importantly, mucus barrier impairment allows microbes to reach the intestinal epithelial cells and can thereby lead to infection and inflammation, as reported in intestinal diseases such as Inflammatory Bowel Disease (IBD)⁸⁷.

Malnutrition enteropathy

Histological studies have revealed that severely malnourished children suffer from severe intestinal mucosal damage, known as malnutrition enteropathy¹². Hallmark features of malnutrition enteropathy include alterations in the small intestinal epithelium architecture with villous atrophy (shortened, leaf-shaped villi), crypt branching, narrowing of the brush border and infiltration with inflammatory cells^{11,12,56} (**Figure 3**). Data on changes in the different epithelial cell types of the intestinal epithelium is scarce with only one study showing a possible reduction in the number of Paneth cells⁸⁸ and another study showing no difference in goblet cell number⁸⁹. Notably, there is increasing recognition that the classical intestinal structure and function are almost universally abnormal in children living in low- and middle-income countries, a finding known as environmental enteropathy⁹⁰. Continuous exposure to enteric pathogens probably underlies these changes of the small intestine as children are often living in conditions with poor hygiene and sanitation. Limited data suggests that the severity of the enteropathy may be higher in severely malnourished children especially in those with concurrent diarrhoea^{11,12}, but this requires further investigation.

Disruptions in intestinal structure have important implications for intestinal barrier function and nutrient absorption (**Figure 3**). Compromised intestinal barrier function has been demonstrated experimentally by increased passage of large sugar molecules (e.g. lactulose : rhamnose ratio) across the intestinal wall in severely malnourished children^{11,91}. This is thought to allow microbial translocation from the intestinal lumen to the systemic circulation, potentially triggering intestinal and systemic inflammation and even sepsis^{4,11}. One study reported histological lesions and disruptions of the intercellular junction proteins claudin-4 and E-cadherin in severely malnourished children, which can contribute to intestinal barrier dysfunction¹¹. Nutrient malabsorption can occur due to villous atrophy, which substantially decreases the absorptive surface area of the small intestine⁵⁷. Carbohydrate malabsorption is prevalent among severely malnourished children, especially of disaccharides such as lactose⁵⁷. Nutrient malabsorption is possibly more severe in children with oedematous malnutrition compared to those with severe wasting⁵⁷. When carbohydrate malabsorption occurs, the unabsorbed molecules draw

fluid into the intestinal lumen leading to osmotic diarrhoea⁹². Absorption of proteins and lipids is likely also compromised⁹³⁻⁹⁶. Important contributors include impaired hepatobiliary function⁹⁷ and exocrine pancreas insufficiency⁹⁵. The lack of impaired digestive enzyme production by the liver and pancreas in combination with a reduced absorptive capacity can lead to protein and lipid malabsorption. The impairments in these essential intestinal functions possibly impede the nutritional recovery of severely malnourished children.

Gatekeepers of intestinal homeostasis

Accumulating data suggests that mTOR signalling, autophagy and mitochondria play key roles in maintaining proper intestinal structure and function⁹⁸⁻¹⁰⁰. Accordingly, dysregulation of these processes have been implicated in the onset and progression of intestinal diseases such as IBD and coeliac disease¹⁰¹⁻¹⁰⁴. These intestinal diseases share similarities with malnutrition enteropathy such as barrier dysfunction, villous atrophy and intestinal inflammation. However, it is unknown how mTORC1, autophagy and mitochondria are affected in the intestine of severely malnourished children, and if alterations contribute to malnutrition enteropathy. In the next sections, I will describe 1) the major functions of these pathways, 2) the reported changes in these pathways in other intestinal diseases and their potential involvement in malnutrition enteropathy.

mTORC1

Organismal growth and viability require an adequate adaptation to stress and changes in nutrient availability. Cells have evolved signalling networks, which respond to various extrinsic and intrinsic stimuli, to adapt cellular metabolism and thereby promote cell proliferation and survival. A key signalling integrator in mammals is the mammalian/mechanistic target of rapamycin (mTOR).

mTOR is a serine/threonine kinase that exists in two structurally and functionally distinct multiprotein complexes, mTORC1 and mTORC2, with only mTORC1 being sensitive to rapamycin and its derivatives called rapalogs¹⁰⁵. mTORC1, an important factor considered in this thesis, responds to a great number of stressors including nutritional, oxidative and endoplasmic reticulum (ER) stress¹⁰⁶. Nutrients and growth factors regulate mTORC1 activity, and amino acids are indispensable for the activation of mTORC1 (**Figure 5**)¹⁰⁷. In nutrient-rich conditions, mTORC1 activation promotes translation and cell growth. In nutrient-deficient conditions, mTORC1 inhibition preserves cellular homeostasis through limiting energy-consuming anabolic processes (e.g. protein synthesis) and promoting

autophagy, a process by which superfluous or damaged proteins and organelles are degraded for nutrient recycling¹⁰⁸. mTORC1 is considered a master regulator of autophagy, because mTORC1 inhibition is needed to initiate the autophagy process¹⁰⁹. More recent studies indicate that mTORC1 also regulates some of the subsequent steps in autophagy such as autophagosome elongation and maturation¹¹⁰.

Autophagy

Autophagy is a catabolic cellular process through which intracellular components are degraded and recycled during physiological conditions as well as in response to cellular stress or nutrient shortage. Based on the mode of cargo delivery to the lysosomes, autophagy can be classified as macroautophagy, microautophagy or chaperone-mediated autophagy¹¹¹. Macroautophagy, hereafter referred to as autophagy, has been most extensively studied and will be discussed here. The process of autophagy can be divided into different steps including initiation, maturation, fusion and degradation (**Figure 5**).

Induction of autophagy is negatively regulated by mTORC1. mTORC1 inhibits autophagy through inactivation of Unc51-like kinase-1 (ULK1) by phosphorylating ULK1 at serine residue 757¹¹². Phosphorylation of ULK1 at S757 disrupts the interaction between ULK1 and energy-sensing AMP-activated protein kinase (AMPK). AMPK is a positive regulator of autophagy¹¹². Following activation of ULK, formation of ULK1 multiprotein complex facilitates the formation of the phagophore¹¹³ and subsequently of autophagosomes¹¹⁴.

Maturation and elongation of the autophagosome membrane is dependent on two ubiquitin-like steps: the conjugation of autophagy-related protein ATG12 to ATG15 and the conversion of LC3I to LC3II (reviewed in ¹¹⁵). LC3-II, the lipidated form, can be incorporated into the membrane of the autophagosome and, together with LC3-I, is most commonly used in experiments as a marker for autophagy activity¹¹⁶. Upon maturation, autophagosomes fuse with lysosomes to form autolysosomes. The contents are then degraded by lysosomal hydrolases. The generated molecular building blocks (e.g. amino acids) are then exported to the cytoplasm to be reused for metabolic processes.

Autophagy can be non-selective or selective. Non-selective autophagy encompasses the usually random uptake of cytoplasm into phagophores, whereas selective autophagy involves the selective removal of superfluous or damaged cellular components¹¹⁷. Selective autophagy has been reported and further studied for different organelles including mitochondria (mitophagy)¹¹⁸, peroxisomes (pexophagy)¹¹⁹ and endoplasmic

reticulum (ER-phagy)¹²⁰. This selective removal of damaged or superfluous organelles is required for the maintenance of proper organelle function, quality control and cellular homeostasis in general.




Figure 5. mTOR and autophagy pathway. mTOR, mammalian/mechanistic target of rapamycin; ULK, Unc51-like kinase-1.

Mitochondria

Mitochondria are double-membrane organelles that support cell survival through production of the energy carrier adenosine triphosphate (ATP) and enable cellular adaptation to stressors¹²¹. Mitochondria are frequently referred to as the 'powerhouse of the cell' as they produce the majority of the ATP required for cell metabolism¹²² through oxidative phosphorylation (reviewed in ¹²³). In addition, mitochondria confer an array of essential cellular functions including calcium handling, signalling, maintaining redox homeostasis and synthesizing precursors for macromolecules (e.g. amino acids)(reviewed in ^{124,125}). Mitochondria are highly dynamic structures which constantly undergo cycles of reshaping, rebuilding and recycling, referred to as mitochondrial dynamics¹²⁶. The processes of mitochondrial dynamics encompass the merging of two mitochondria into one (fusion), the division of one mitochondrion into two mitochondria (fission) and selective degradation of dysfunctional mitochondria (mitophagy) (reviewed in ¹²⁶). These processes are important for regulating the function of these organelles in response to environmental and metabolic changes. Mitochondria can be challenged by numerous stressors including increased reactive oxygen species (ROS)¹²⁷. Maladaptive stress responses of mitochondria can compromise their function and can be detrimental for cell survival¹²⁷.

Dysregulated mTORC1, autophagy and mitochondrial homeostasis in intestinal diseases and malnutrition enteropathy

Alterations in mTORC1, autophagy and mitochondria have been described and implicated in the pathogenesis of various intestinal diseases. Increased activation of mTORC1 in the intestinal epithelium has been reported in patients with active coeliac disease¹⁰¹ and IBD^{103,128,129}. The onset or progression of IBD has been strongly associated with reductions in autophagy in the intestinal epithelium^{103,130}, but the evidence for impaired autophagy in coeliac disease is limited to a gene expression study in duodenal biopsies¹³¹ and preclinical data¹³². Involvement of epithelial mitochondrial dysfunction is strongly implicated during the onset and course of IBD^{104,133}.

In severely malnourished children, no data about mTORC1 activity in the intestine is available. Data on autophagy is sparse, ranging from no apparent changes in autophagosomes to enlarged autophagosomes with unclear clinical implications¹³⁴⁻¹³⁷. Few studies have reported, sometimes opposing, mitochondrial morphological changes in the small intestine of severely malnourished children¹³⁴⁻¹³⁷. These morphological changes may be more evident in children with severe intestinal disease^{134,136}. Dymorphic mitochondria have also been reported in other organs of severely malnourished children^{138,139}. Involvement of dysregulated autophagy and mitochondrial homeostasis is a realistic possibility in malnutrition enteropathy given the histological reports and knowledge from intestinal diseases that share similarities with malnutrition enteropathy. There is a compelling need for new information about mTORC1, autophagy and mitochondria in the small intestine of severely malnourished children.

Bridging the knowledge gaps in malnutrition enteropathy with in-vivo and ex-vivo models

Studying underlying mechanisms in severely malnourished children is challenging given the vulnerability of this population. For example, studying mechanisms behind impaired intestinal health in severe malnutrition would ideally use intestinal biopsies, which require invasive endoscopic procedures. Although limited, preclinical models have been developed to generate a better understanding of severe malnutrition and its pathophysiology.

Animal models of (severe) malnutrition

Animal models are extensively used in scientific research and have helped to unravel the pathophysiology of numerous diseases. Features of severe malnutrition have been reproduced in various species using diverse methods (e.g. caloric or protein restriction). However, no standards for defining severe malnutrition have been established for laboratory animals. Thus, the validity of a malnutrition animal model and the characteristics that need to be modelled largely depend on the specific research question. To illustrate, when the aim is to shed light on oedematous malnutrition it is a prerequisite to recapitulate essential features of oedematous malnutrition in animals such as oedema. Yet, oedema is not present in all animal models. Features of oedematous malnutrition were successfully reproduced in monkeys¹⁴⁰⁻¹⁴², pigs¹⁴³ and rats¹⁴⁴ that were fed a low-protein diet. Ideally, animal models should be close to human physiology to enable clinical translatability, for example through the use of monkeys or pig models. However, ethical considerations, expenses and long gestation periods make these species impractical for high turnover experiments. Therefore, rodents have been commonly used in research in general, but also for malnutrition studies specifically. In the next section, I will discuss what types of malnutrition animal models have been established and report specifically on intestinal structure and function.

Malnutrition animal models to study the impact on the intestine

As described previously, the physiology of the small intestine in severely malnourished children is disrupted with changes in the architecture, function and immune system (**Figure 3**). The impact of malnutrition on the small intestine has been evaluated in different animal models of malnutrition, which are discussed in more detail below. Malnutrition in these models was mainly induced by feeding animals deficient diets and was sometimes combined with an additional intestinal insult (e.g. pathogen). Although different forms of nutritional deprivation can induce malnutrition in animals, the impact of this on the intestine and the extent of characterization of intestinal changes in these models differs considerably (**Table 1**). Commonly used forms of nutritional deprivation include caloric restriction (CR), protein deprivation and use of a regional based diet.

Nutritional deprivation

Limitation of daily caloric intake by 15% to 30% did not impact on intestinal permeability and led to only minor changes in small intestinal morphology (reviewed in ^{145,146})¹⁴⁷.

Similarly, a recent study showed that further increasing caloric restriction to 50% for 3 weeks did not increase intestinal permeability in young mice¹⁴⁵. Notably, severe forms of caloric restriction might be stressful for rodents with reports of increased plasma corticosterone levels (25% CR, juvenile rats)¹⁴⁸ and signs of anxiety and depression (50% CR, rats)¹⁴⁹. Given the ethical considerations of increased stress levels in CR, ad libitum deficient diets could be a better alternative such as low-protein or regional based diets.

Protein-deficient diets reflect the type of diets that are common in developing countries, where staple foods, such as maize, are often high in carbohydrates and low in protein. The effects of a low-protein diet (LPD) on the intestine that have been described in the literature are highly variable (**Table 1**), which may be in part related to the severity of the protein restriction, the life stage of the animal (e.g. young or adult) and/or the animal species that was used. Importantly, the impact of protein deprivation on nutrient absorption has not been studied in these models.

As micronutrient intake is often also low in malnourished children²⁰, rodent diets have been formulated that reflect regional dietary patterns and mimic both macronutrient (low-protein) and micronutrient deficiencies. Studies that have used these regional diets – the Malawian diet, the Regional Basic Diet (RBD) or the Maize diet – have most extensively studied the small intestine using the RBD (**Table 1**). The RBD reflects the dietary pattern from the northeast Brazilian population¹⁵⁰, whereas the Maize diet is based on the publication of Dr. Cecily Williams in 1933 that noted that kwashiorkor occurred in children who were primarily fed a maize-based diet²⁴. Yet, the study of nutrient absorption using these diets is very limited.

As the impact of nutritional deprivation by itself is not always sufficient to produce intestinal barrier dysfunction and intestinal inflammation, some studies have combined protein deprivation with a microbial challenge or indomethacin use, a non-steroidal anti-inflammatory drug (NSAID)(**Table 1**).

Nutritional deprivation with additional intestinal insult

High exposure to pathogens could play a role in the development and persistence of malnutrition enteropathy. In pathogen-induced enteropathy models, both parasites (*Cryptosporidium parvum*, *Giardia lamblia*) and bacteria (E. coli + Bacteroidales) have successfully induced some features of malnutrition enteropathy (**Table 1**). Indomethacin, a NSAID, was also used to induce enteropathy in malnourished mice based on the described use in enteropathy induction in mice fed a normal diet¹⁵¹. However, the

findings in these models may be pathogen(s) or NSAID specific, which decreases the reproducibility and validity.

In conclusion, nutritional deprivation (except caloric restriction) with or without an additional intestinal insult can reproduce some important characteristics of malnutrition enteropathy in animals. However, the evaluation of intestinal changes is only fragmentary (**Table 1**). This hampers a more in-depth understanding of underlying mechanisms and testing of potential therapeutic interventions. Thus, a malnutrition model is needed that comprehensively characterizes intestinal changes both in structure and function.

Table 1. Small intestinal alterations in malnutrition animal models.

Insult	Structure	Barrier function	Nutrient absorption
Protein restriction			
0% protein , 2 weeks adult rats ¹⁵² , jejunum	↓ VH	Not assessed	Not assessed
4% protein , 20 days juvenile rats ¹⁵³ , ileum	VH: not assessed CD: no effect	<ul style="list-style-type: none"> • ↑ permeability small molecules (reduced TEER) • Non-significant increase in permeability to 4 and 40 kDa FITC-dextran • ↓ protein levels TJ-protein <i>Ocln</i> 	Not assessed
4% protein , 3 weeks guinea pigs ¹⁵⁴ , jejunum	Not assessed	<ul style="list-style-type: none"> • ↑ permeability to small molecules (Ussing chamber), but not to macromolecules • 10% reduction of TJ strands 	Not assessed
5.8% protein , 3 weeks weanling mice ¹⁴⁵ , jejunum	VH: no impact CD: no impact	<ul style="list-style-type: none"> • No change in permeability (Ussing chamber) or permeability to 4kDa FITC-dextran† • ↓ mRNA expression <i>Muc2</i> and TJ-protein <i>Ocln</i> 	Not assessed
7% protein , 3 weeks weanling mice ¹⁵⁵ , jejunum	VH: no impact	<ul style="list-style-type: none"> • ↑ permeability to 4 kDa FITC-dextran • ↓ mRNA expression TJ-protein <i>ZO-1</i> and ↑ pore-forming TJ-protein <i>Cldn-2</i> 	Not assessed

Insult	Structure	Barrier function	Nutrient absorption
Regional diets			
<i>Regional basic diet (RBD)</i>			
7% protein, 8.2% fat, reduced micronutrients			
7 days , RBD juvenile mice ¹⁵⁶ , ileum	VH: no impact ↓ CD	<ul style="list-style-type: none"> No change in permeability (Ussing chamber) No change protein levels pore-forming TJ-protein <i>Cldn2</i> or <i>Ocln</i> 	No change SGLT-1 or PEPT transporters
10 days , RBD weanling mice ¹⁵⁷ , ileum	↓ VH:CD ratio	Not assessed	Not assessed
3 weeks , RBD weanling mice ¹⁵⁸ , jejunum	↓ VH, CD and VH:CD ratio	<ul style="list-style-type: none"> ↑ ex vivo permeability to 4kDa FITC-Dextran ↓ TER ↑ TJ-protein <i>Cldn3</i> expression in crypts (IF, WB) 	Not assessed
14 days , RBD weanling rats ¹⁵⁹ , jejunum	↓ VH, ↑ CD and ↓ VH:CD ratio	<ul style="list-style-type: none"> ↑ bacterial translocation to spleen ↓ goblet cell numbers 	Not assessed
<i>Maize diet</i>			
6.4% protein, 3.4% fat, reduced micronutrients			
4 weeks juvenile pigs ¹⁶⁰ , jejunum, ileum	↓ VH	Not assessed	↓ disaccharidase and peptidase activity (only ileum)
<i>Malawian Diet (M8)</i> , mice ¹⁶¹	Impact on intestine not assessed		
Low-protein diet with a microbial challenge			
Cryptosporidium infection			
<i>C. parvum</i> + 2% LPD weanling mice ¹⁶² , ileum	↓ VH ↑ CD	Not assessed	Not assessed
<i>C. Parvum</i> + 2% LPD weanling mice ¹⁵⁷ , ileum	↓ VH:CD ratio	<ul style="list-style-type: none"> ↓ protein levels TJ-protein <i>Ocln</i> ↑ internalization of TJ-protein <i>Ocln</i> ↑ protein levels pore-forming TJ-protein <i>Cldn2</i> 	Not assessed
Giardia lamblia infection			
<i>G. Lamblia</i> + 3% LPD weanling mice ¹⁶³	Not assessed	Not assessed	↓ glucose and alanine absorption
<i>G. duodenalis</i> + 4.3% LPD, juvenile mice ¹⁶⁴ , ileum	↓ VH and CD	Not assessed ↓ goblet cell number	Not assessed
<i>G. lamblia</i> , 2% LPD weanling mice ¹⁶⁵ , duodenum	↓ VH ↓ VH:CD ratio	Not assessed	Not assessed

Insult	Structure	Barrier function	Nutrient absorption
Bacterial infection			
<i>E. coli</i> + Bacteroidales 7% protein, weanling mice ¹⁵⁵ , jejunum	↓ VH ↓ VH:CD ratio	<ul style="list-style-type: none"> ↑ permeability to 4kDa FITC-dextran 	Not assessed
Low-protein diet with another gastrointestinal trigger			
Indomethacin , oral, 7 days, 5.8% protein, 3 weeks, weanling mice ¹⁴⁵ , jejunum	VH: no impact CD: no impact	<ul style="list-style-type: none"> ↑ permeability to 4 kDa FITC-dextran ↓ mRNA expression TJ-protein <i>Ocln</i> 	Not assessed

† Increased permeability after 14 days low-protein diet

CD, crypt depth; Cldn, claudin; FITC, Fluorescein isothiocyanate; IF, immunofluorescence; LPD, low-protein diet; Muc2, mucin 2; Ocln, occludin; SGLT1, sodium glucose cotransporters; PEPT, intestinal peptidase transporter, TEER, transepithelial electrical resistance, TER, transepithelial resistance, TJ, tight junction; VH, villous height; ZO-1, zonulin-1

In vitro models of severe malnutrition

An *in vitro*, cell-based model may be more suitable to study the impact of nutritional deficiencies on metabolic and signaling pathways. Cell culture has the advantage that many interventions can be tested rapidly and detailed time-course data can be obtained. There is currently no *in vitro* model of severe malnutrition. Yet, studies have used some form of starvation, as a proxy of malnutrition: serum starvation in intestinal cell lines to complement findings from *in vivo* malnutrition studies¹⁶⁶ or amino acid deprivation in isolated porcine intestinal epithelial cells¹⁶⁷. In the latter study, starvation for non-essential amino acids increased permeability and decreased TJ proteins zonulin-1 and claudin-1, which indicates a decline in barrier function. However, two-dimensional cell cultures are less suitable to study functional organ properties. Advances in three-dimensional cultures, in particular organoids, have opened new avenues for the development of more physiological *in vitro* models of organ function and diseases^{67,168}. Intestinal organoids are derived from self-organizing stem cells that can recapitulate the *in vivo* architecture and functionality of the original tissue (i.e. barrier function and nutrient absorption in small intestinal organoids)^{169,170}. Organoids are cultured in a 3D extracellular matrix (e.g. Matrigel) and supplemented with a combination of growth factors identical to those found in the stem cells niche *in vivo* (i.e. epidermal growth factor, Noggin, R-spondin-1)⁶⁷. These molecules allow the small intestinal organoids to continuously expand, resembling the cellular organization and self-renewal dynamics of the small intestinal epithelium. Some studies have used intestinal organoids to investigate the need of specific amino acids for proper stem cell function. Moore et al. showed that glutamine deprivation decreased epithelial proliferation and induced crypt atrophy¹⁷¹. Saito et al. specifically evaluated

methionine deprivation and demonstrated that this suppressed stem cell proliferation and promoted differentiation¹⁷². Although some form of amino acid deprivation, as a proxy of malnutrition, was used, these stem cell-focused studies did not fully characterize the impact of ‘malnutrition’ on intestinal organoids. They only removed particular amino acids and did not investigate the relation between intestinal organoid function, organelles and pathway disruption. There is a need for models like this in order to better understand pathophysiology at the intestinal epithelial level and to test interventions in a high-throughput manner. Furthermore, continuous expansion of organoids makes it possible to experiment on human cells, and it also has the potential to significantly reduce the use of laboratory animals.

Aims and outline of this thesis

The aims of this thesis were 1) to gain insight into factors that contribute to diarrhoea and poor clinical outcomes in hospitalized severely malnourished children, and 2) to study small intestinal dysfunction and identify potential underlying mechanisms in severe malnutrition.

In this thesis, clinical studies were combined with two malnutrition model systems (mouse and intestinal organoids)(**Figure 6**). In **part I** of this thesis, I investigated the role of different nutritional, microbial and inflammatory factors in diarrhoeal disease and poor clinical outcomes during admission in severely malnourished children. In **part II** of this thesis, I established and characterized a mouse model and intestinal organoid model of malnutrition enteropathy. To assess the potential of organoid models in malnutrition research in a broader perspective, I collaborated with a fellow PhD student and also added a hepatic organoid model of severe malnutrition. In the mouse and organoid models, I investigated potential mechanisms involved in intestinal dysfunction and tested interventions. In **part III** of this thesis, I discuss the future perspectives and implications of the findings for potential therapeutic interventions.

Part I – Clinical studies

Chapter 2 evaluates three commonly-used “transition-phase” diets with different carbohydrate content by comparing biochemical and clinical outcomes. Moreover, it discusses the potential role of carbohydrate malabsorption in the onset and/or continuation of diarrhoea in severely malnourished children during inpatient treatment.

Chapter 3 provides an insight into the intestinal and inflammatory mechanisms

underlying deaths in hospitalized severely malnourished children. **Chapter 4** reports on the prevalence and clearance of intestinal pathogens in severely malnourished children during hospital admission. Furthermore, it describes the contribution of these intestinal pathogens to diarrhoeal disease and other clinical outcomes.

Part II – Preclinical studies

Chapter 5 presents a novel mouse model of malnutrition enteropathy with characterization of structural and functional intestinal changes. Furthermore, it shows changes in mTORC1 activation, autophagy and mitochondria, and shows the positive impact of rapamycin on the small intestine. **Chapter 6** describes the use of intestinal organoids as a model for malnutrition enteropathy and liver dysfunction. It shows how amino acid deprivation disrupts structure, function and mitochondrial and peroxisomal health in intestinal and hepatic organoids. Moreover, it describes if interventions such as rapamycin and fenofibrate can preserve homeostasis in intestinal organoids and hepatic organoids, respectively.

Part III – Future perspectives

Chapter 7 provides a general discussion of this thesis' findings and focuses on future perspectives.




Figure 6. The approach used in this thesis. Clinical trials provide information of the patient population of interest, severely malnourished children. In the malnutrition mouse model, intestinal changes and underlying mechanisms can be studied. In intestinal organoids, the impact of severe malnutrition on the intestinal epithelium and underlying mechanisms can be studied, including barrier function, organelle dynamics and stem cell proliferation and differentiation.

References

1. UNICEF, WHO, World Bank. United Nations Children's Fund, World Health Organization & World Bank Group. Levels and trends in child malnutrition: Key findings of the 2020 Edition of the Joint Child Malnutrition Estimates. [Internet]. Geneva: WHO. 2020. Available from: <https://www.who.int/publications/i/item/jme-2020-edition>
2. Black RE, Victora CG, Walker SP, Bhutta ZA, Christian P, de Onis M, et al. Maternal and child undernutrition and overweight in low-income and middle-income countries. *Lancet*. 2013;382:427–51.
3. Collins S, Sadler K, Dent N, Khara T, Guerrero S, Myatt M, et al. Key issues in the success of community-based management of severe malnutrition. *Food Nutr Bull*. 2006;27:S49-82.
4. Attia S, Versloot CJ, Voskuil W, van Vliet SJ, Di Giovanni V, Zhang L, et al. Mortality in children with complicated severe acute malnutrition is related to intestinal and systemic inflammation: an observational cohort study. *Am J Clin Nutr*. 2016;104(5):1441–9.
5. Kerac M, Bunn J, Chagaluka G, Bahwere P, Tomkins A, Collins S, et al. Follow-up of post-discharge growth and mortality after treatment for severe acute malnutrition (FuSAM study): a prospective cohort study. *PLoS One*. 2014;9(6):e96030.
6. Munthali T, Jacobs C, Sitali L, Dambe R, Michelo C. Mortality and morbidity patterns in under-five children with severe acute malnutrition (SAM) in Zambia: a five-year retrospective review of hospital-based records (2009-2013). *Arch Public Health*. 2015;73(1):23.
7. Ubesie AC, Ibeziako NS, Ndiokwelu CI, Uzoka CM, Nwafor CA. Under-five protein energy malnutrition admitted at the University of Nigeria Teaching Hospital, Enugu: a 10 year retrospective review. *Nutr J*. 2012;11:43.
8. Talbert A, Thuo N, Karisa J, Chesaro C, Ohuma E, Ignas J, et al. Diarrhoea complicating severe acute malnutrition in Kenyan children: a prospective descriptive study of risk factors and outcome. *PLoS One*. 2012;7(6):e38321.
9. Grenov B, Lanyero B, Nabukeera-Barungi N, Namusoke H, Ritz C, Friis H, et al. Diarrhea, Dehydration, and the Associated Mortality in Children with Complicated Severe Acute Malnutrition: A Prospective Cohort Study in Uganda. *J Pediatr*. 2019;210:26–33.
10. Nabukeera-Barungi N, Grenov B, Lanyero B, Namusoke H, Mupere E, Christensen VB, et al. Predictors of mortality among hospitalized children with severe acute malnutrition: a prospective study from Uganda. *Pediatr Res*. 2018;84(1):92–8.
11. Amadi B, Besa E, Zyambo K, Kaonga P, Louis-Auguste J, Chandwe K, et al. Impaired Barrier Function and Autoantibody Generation in Malnutrition Enteropathy in Zambia. *EBioMedicine*. 2017;22:191–9.
12. Attia S, Feenstra M, Swain N, Cuesta M, Bandsma RHJ. Starved Guts: Morphologic and Functional Intestinal Changes in Malnutrition. *J Pediatr Gastroenterol Nutr*. 2017;65(5):491–5.
13. Sullivan PB. Studies of the small intestine in persistent diarrhea and malnutrition: the Gambian experience. *J Pediatr Gastroenterol Nutr*. 2002;34:S11-3.
14. World Health Organization. What is malnutrition? [Internet]. 2021. Available from: <https://www.who.int/news-room/fact-sheets/detail/malnutrition>
15. WHO Child Growth Standards: Length/height-for-age, weight-for-age, weight-for-length, weight-for-height and body mass index-for-age: methods and development. WHO. 2006.
16. Lelijveld N, Seal A, Wells JC, Kirkby J, Opondo C, Chimwezi E, et al. Chronic disease outcomes after severe acute malnutrition in Malawian children (ChroSAM): a cohort study. *Lancet Glob Heal*. 2016;4(9):e654-62.

17. Alam MA, Richard SA, Fahim SM, Mahfuz M, Nahar B, Das S, et al. Impact of early-onset persistent stunting on cognitive development at 5 years of age: Results from a multi-country cohort study. *PLoS One*. 2020;15(1):e0227839.
18. World Health Organization. Management of severe malnutrition: a manual for physicians and other senior health workers. 1999.
19. WHO. WHO child growth standards and the identification of severe acute malnutrition in infants and children [Internet]. Available from: http://apps.who.int/iris/bitstream/10665/44129/1/9789241598163_eng.pdf?ua=1
20. Bhutta ZA, Berkley JA, Bandsma RHJ, Kerac M, Trehan I, Briend A. Severe childhood malnutrition. *Nat Rev Dis Prim*. 2017;3:17067.
21. Autret M, Behar M. Infantile multiple deficiency syndrome in Central America (Kwashiorkor). *Bull World Health Organ*. 1954;11(6):891–966.
22. Normet L. La Bouffissure d’Annam. *Bull Soc Pathol Exot*. 1926;19:207–13.
23. Procter RA. Medical work in a native reserve. *Kenya Med J*. 1926;(3):284–9.
24. Williams CD. A nutritional disease of childhood associated with a maize diet. *Arch Dis Child*. 1933;8(48):423–33.
25. Williams C. Kwashiorkor, a nutritional disease associated with a maize diet. *Lancet*. 1935;224:1151–2.
26. Brock J, Autret M. Kwashiorkor in Africa [Internet]. World Health Organization. 1952. Available from: <https://apps.who.int/iris/handle/10665/40717>
27. Autret M, Béhar M. Síndrome Policarenal Infantil (Kwashiorkor) and Its Prevention in Central America. *FAO Nutrition Studies No.13*, Food and Agriculture Organization. 1954.
28. Waterlow J, Vergara A. Protein Malnutrition in Brazil. *FAO Nutritional studies No.14* Rome. Food and Agriculture Organization. 1956.
29. Joint FAO/WHO Expert Committee on Nutrition : third report [of a meeting held in Fajara, Gambia, from 28 November to 3 December 1952] [Internet]. World Health Organization; 1953. (World Health Organization technical report series ; no. 72). Available from: <https://apps.who.int/iris/handle/10665/40219>
30. Burgess A, Dean R. Malnutrition and Food Habits. Report of an International and Interprofessional Conference. London. 1962.
31. Waterlow JC. Classification and definition of protein-calorie malnutrition. *Br Med J*. 1972;3(5826):566–9.
32. Classification of infantile malnutrition. *Lancet*. 1970;2(7667):302–3.
33. Frison S, Checchi F, Kerac M. Omitting edema measurement: how much acute malnutrition are we missing? *Am J Clin Nutr*. 2015;102(5):1176–81.
34. Luis Alvarez J, Dent N, Browne L, Myatt M, Briend A, Kravec J, et al. Putting Child Kwashiorkor on the map [Internet]. 2016. Available from: <http://files.enonline.net/attachments/2485/Putting-Kwashiorkor-on-the-Map.pdf>
35. UNICEF. Improving Child Nutrition: The achievable imperative for global progress. Vol. 18, NCSL legisbrief. 2013. 4 p.
36. Wharton B. Hypoglycaemia in children with kwashiorkor. *Lancet*. 1970;1(7639):171–3.
37. Bandsma RHJ, Mendel M, Spoelstra MN, Reijngoud D-J, Boer T, Stellaard F, et al. Mechanisms behind decreased endogenous glucose production in malnourished children. *Pediatr Res*. 2010;68(5):423–8.

38. Nduhukire T, Atwine D, Rachel L, Byonanebye JE. Predictors of in-hospital mortality among under-five children with severe acute malnutrition in South-Western Uganda. *PLoS One*. 2020;15(6):e0234343.
39. Ngari MM, Fegan G, Mwangome MK, Ngama MJ, Mturi N, Scott JAG, et al. Mortality after Inpatient Treatment for Severe Pneumonia in Children: a Cohort Study. *Paediatr Perinat Epidemiol*. 2017;31(3):233–42.
40. O'Reilly CE, Jaron P, Ochieng B, Nyaguara A, Tate JE, Parsons MB, et al. Risk factors for death among children less than 5 years old hospitalized with diarrhea in rural western Kenya, 2005–2007: a cohort study. *PLoS Med*. 2012;9(7):e1001256.
41. Caulfield LE, de Onis M, Blössner M, Black RE. Undernutrition as an underlying cause of child deaths associated with diarrhea, pneumonia, malaria, and measles. *Am J Clin Nutr*. 2004;80(1):193–8.
42. Pelletier DL, Frongillo EAJ, Schroeder DG, Habicht JP. The effects of malnutrition on child mortality in developing countries. *Bull World Health Organ*. 1995;73(4):443–8.
43. ENN. Aetiology of Wasting [Internet]. Emergency Nutrition Network (ENN); 2018. Available from: <https://www.enonline.net/resources/aetiologyofwasting>
44. Cohen S, Nathan JA, Goldberg AL. Muscle wasting in disease: molecular mechanisms and promising therapies. *Nat Rev Drug Discov*. 2015;14(1):58–74.
45. André Briend PhD MD. Kwashiorkor: still an enigma – the search must go on [Internet]. Emergency Nutrition Network (ENN); 2014. Available from: <https://www.enonline.net/kwashiorkorstillanenigma>
46. Pham T-P-T, Tidjani Alou M, Bachar D, Levasseur A, Brah S, Alhousseini D, et al. Gut Microbiota Alteration is Characterized by a Proteobacteria and Fusobacteria Bloom in Kwashiorkor and a Bacteroidetes Paucity in Marasmus. *Sci Rep*. 2019;9(1):9084.
47. WHO. Pocket Book of Hospital Care for Children: Guidelines for the Management of Common Childhood Illnesses. 2nd ed. 2013. 125–143 p.
48. WHO. Guideline: Updates on the management of severe acute malnutrition in infants and children. 2013;1–123.
49. Murray E, Manary M. Home-based therapy for severe acute malnutrition with ready-to-use food. *Paediatr Int Child Health*. 2014;34(4):266–70.
50. Alvarez Morán JL, Alé GBF, Charle P, Sessions N, Doumbia S, Guerrero S. The effectiveness of treatment for Severe Acute Malnutrition (SAM) delivered by community health workers compared to a traditional facility based model. *BMC Health Serv Res*. 2018;18(1):207.
51. Burza S, Mahajan R, Marino E, Sunyoto T, Shandilya C, Tabrez M, et al. Community-based management of severe acute malnutrition in India: new evidence from Bihar. *Am J Clin Nutr*. 2015;101(4):847–59.
52. Friedli N, Stanga Z, Sobotka L, Culkin A, Kondrup J, Laviano A, et al. Revisiting the refeeding syndrome: Results of a systematic review. *Nutrition*. 2017;35:151–60.
53. Karunaratne R, Sturgeon JP, Patel R, Prendergast AJ. Predictors of inpatient mortality among children hospitalized for severe acute malnutrition: a systematic review and meta-analysis. *Am J Clin Nutr*. 2020;112(4):1069–79.
54. Gavhi F, Kuonza L, Musekiwa A, Motaze NV. Factors associated with mortality in children under five years old hospitalized for Severe Acute Malnutrition in Limpopo province, South Africa, 2014–2018: A cross-sectional analytic study. *PLoS One*. 2020;15(5):e0232838.

55. Tickell KD, Denno DM. Inpatient management of children with severe acute malnutrition: a review of WHO guidelines. *Bull World Health Organ.* 2016;94(9):642–51.
56. Farràs M, Chandwe K, Mayneris-Perxachs J, Amadi B, Louis-Auguste J, Besa E, et al. Characterizing the metabolic phenotype of intestinal villus blunting in Zambian children with severe acute malnutrition and persistent diarrhea. *PLoS One.* 2018;13(3):e0192092.
57. Kvissberg MA, Dalvi PS, Kerac M, Voskuil W, Berkley JA, Priebe MG, et al. Carbohydrate malabsorption in acutely malnourished children and infants: a systematic review. *Nutr Rev.* 2016;74(1):48–58.
58. Ross M. *Histology: a text and atlas.* 5th ed. Philadelphia: Lippincott Williams & Wilkins; 2005. 518–595 p.
59. Ramakrishna BS. Role of the gut microbiota in human nutrition and metabolism. *J Gastroenterol Hepatol.* 2013 Dec;28 Suppl 4:9–17.
60. Roediger WE. Utilization of nutrients by isolated epithelial cells of the rat colon. *Gastroenterology.* 1982;83(2):424–9.
61. Turner JR. Intestinal mucosal barrier function in health and disease. *Nat Rev Immunol.* 2009;9(11):799–809.
62. Gehart H, Clevers H. Tales from the crypt: new insights into intestinal stem cells. *Nat Rev Gastroenterol Hepatol.* 2019;16(1):19–34.
63. Arike L, Seiman A, van der Post S, Rodríguez Piñeiro AM, Ermund A, Schütte A, et al. Protein Turnover in Epithelial Cells and Mucus along the Gastrointestinal Tract Is Coordinated by the Spatial Location and Microbiota. *Cell Rep.* 2020;30(4):1077–1087.e3.
64. Ireland H, Houghton C, Howard L, Winton DJ. Cellular inheritance of a Cre-activated reporter gene to determine Paneth cell longevity in the murine small intestine. *Dev Dyn.* 2005;233(4):1332–6.
65. Clevers H. The intestinal crypt, a prototype stem cell compartment. *Cell.* 2013;154(2):274–84.
66. Krndija D, El Marjou F, Guirao B, Richon S, Leroy O, Bellaiche Y, et al. Active cell migration is critical for steady-state epithelial turnover in the gut. *Science.* 2019;365(6454):705–10.
67. Sato T, Vries RG, Snippert HJ, van de Wetering M, Barker N, Stange DE, et al. Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche. *Nature.* 2009;459(7244):262–5.
68. Rodríguez-Colman MJ, Schewe M, Meerlo M, Stigter E, Gerrits J, Pras-Raves M, et al. Interplay between metabolic identities in the intestinal crypt supports stem cell function. *Nature.* 2017;543(7645):424–7.
69. Cheng H, Leblond CP. Origin, differentiation and renewal of the four main epithelial cell types in the mouse small intestine. V. Unitarian Theory of the origin of the four epithelial cell types. *Am J Anat.* 1974;141(4):537–61.
70. Barker N, van Es JH, Kuipers J, Kujala P, van den Born M, Cozijnsen M, et al. Identification of stem cells in small intestine and colon by marker gene Lgr5. *Nature.* 2007;449(7165):1003–7.
71. Tian H, Biehs B, Warming S, Leong KG, Rangell L, Klein OD, et al. A reserve stem cell population in small intestine renders Lgr5-positive cells dispensable. *Nature.* 2011;478(7368):255–9.
72. Takeda N, Jain R, LeBoeuf MR, Wang Q, Lu MM, Epstein JA. Interconversion between intestinal stem cell populations in distinct niches. *Science.* 2011;334(6061):1420–4.
73. Buczaccki SJA, Zecchini HI, Nicholson AM, Russell R, Vermeulen L, Kemp R, et al. Intestinal label-retaining cells are secretory precursors expressing Lgr5. *Nature.* 2013;495(7439):65–9.

74. van Es JH, Sato T, van de Wetering M, Lyubimova A, Yee Nee AN, Gregorieff A, et al. Dll1+ secretory progenitor cells revert to stem cells upon crypt damage. *Nat Cell Biol.* 2012;14(10):1099-104.
75. Tetteh PW, Basak O, Farin HF, Wiebrands K, Kretschmar K, Begthel H, et al. Replacement of Lost Lgr5-Positive Stem Cells through Plasticity of Their Enterocyte-Lineage Daughters. *Cell Stem Cell.* 2016;18(2):203-13.
76. Jadhav U, Saxena M, O'Neill NK, Saadatpour A, Yuan G-C, Herbert Z, et al. Dynamic Reorganization of Chromatin Accessibility Signatures during Dedifferentiation of Secretory Precursors into Lgr5+ Intestinal Stem Cells. *Cell Stem Cell.* 2017;21(1):65-77.e5.
77. Garcia MA, Nelson WJ, Chavez N. Cell-Cell Junctions Organize Structural and Signaling Networks. *Cold Spring Harb Perspect Biol.* 2018;10(4).
78. Hansson GC. Mucus and mucins in diseases of the intestinal and respiratory tracts. *J Intern Med.* 2019;285(5):479-90.
79. Ermund A, Schütte A, Johansson ME V, Gustafsson JK, Hansson GC. Studies of mucus in mouse stomach, small intestine, and colon. I. Gastrointestinal mucus layers have different properties depending on location as well as over the Peyer's patches. *Am J Physiol Gastrointest Liver Physiol.* 2013;305(5):G341-7.
80. Bevins CL, Salzman NH. Paneth cells, antimicrobial peptides and maintenance of intestinal homeostasis. *Nat Rev Microbiol.* 2011;9(5):356-68.
81. Johansson ME V, Larsson JMH, Hansson GC. The two mucus layers of colon are organized by the MUC2 mucin, whereas the outer layer is a legislator of host-microbial interactions. *Proc Natl Acad Sci U S A.* 2011;108 Suppl(Suppl 1):4659-65.
82. Martens EC, Neumann M, Desai MS. Interactions of commensal and pathogenic microorganisms with the intestinal mucosal barrier. *Nat Rev Microbiol.* 2018;16(8):457-70.
83. Johansson ME V, Hansson GC. Immunological aspects of intestinal mucus and mucins. *Nat Rev Immunol.* 2016;16(10):639-49.
84. Paone P, Cani PD. Mucus barrier, mucins and gut microbiota: the expected slimy partners? *Gut.* 2020;69(12):2232-43.
85. Laudisi F, Di Fusco D, Dinallo V, Stoffi C, Di Grazia A, Marafini I, et al. The Food Additive Maltodextrin Promotes Endoplasmic Reticulum Stress-Driven Mucus Depletion and Exacerbates Intestinal Inflammation. *Cell Mol Gastroenterol Hepatol.* 2019;7(2):457-73.
86. Willing BP, Russell SL, Finlay BB. Shifting the balance: antibiotic effects on host-microbiota mutualism. *Nat Rev Microbiol.* 2011;9(4):233-43.
87. Johansson ME V, Gustafsson JK, Holmén-Larsson J, Jabbar KS, Xia L, Xu H, et al. Bacteria penetrate the normally impenetrable inner colon mucus layer in both murine colitis models and patients with ulcerative colitis. *Gut.* 2014;63(2):281-91.
88. Béhar M, Arroyave G, Tejada C. Desnutrición severa de la infancia. III. Aspectos patológicos. *Rev Col Med Guatemala.* 1956;(7):235.
89. Burman D. The jejunal mucosa in kwashiorkor. *Arch Dis Child.* 1965;40(213):526-31.
90. Crane RJ, Jones KDJ, Berkley JA. Environmental enteric dysfunction: an overview. *Food Nutr Bull.* 2015;36(1 Suppl):S76-87.
91. Boaz RT, Joseph AJ, Kang G, Bose A. Intestinal permeability in normally nourished and malnourished children with and without diarrhea. *Indian Pediatr.* 2013;50(1):152-3.
92. Eherer AJ, Fordtran JS. Fecal osmotic gap and pH in experimental diarrhea of various causes. *Gastroenterology.* 1992;103(2):545-51.

93. Murphy JL, Badaloo A V, Chambers B, Forrester TE, Wootton SA, Jackson AA. Maldigestion and malabsorption of dietary lipid during severe childhood malnutrition. *Arch Dis Child.* 2002;87(6):522-5.
94. Schneider RE, Viteri FE. Luminal events of lipid absorption in protein-calorie malnourished children; relationship with nutritional recovery and diarrhea. II. Alterations in bile acid content of duodenal aspirates. *Am J Clin Nutr.* 1974;27(8):788-96.
95. Bartels RH, Meyer SL, Stehmann TA, Bourdon C, Bandsma RHJ, Voskuil WP. Both Exocrine Pancreatic Insufficiency and Signs of Pancreatic Inflammation Are Prevalent in Children with Complicated Severe Acute Malnutrition: An Observational Study. *J Pediatr.* 2016;174:165-70.
96. Iputo JE. Protein-losing enteropathy in Transkeian children with morbid protein-energy malnutrition. *S Afr Med J.* 1993;83(8):588-9.
97. Zhang L, Voskuil W, Mouzaki M, Groen AK, Alexander J, Bourdon C, et al. Impaired Bile Acid Homeostasis in Children with Severe Acute Malnutrition. *PLoS One.* 2016;11(5):e0155143.
98. Kaur H, Moreau R. Role of mTORC1 in intestinal epithelial repair and tumorigenesis. *Cell Mol Life Sci.* 2019;76(13):2525-46.
99. Haq S, Grondin J, Banskota S, Khan WI. Autophagy: Roles in intestinal mucosal homeostasis and inflammation. *J Biomed Sci.* 2019;26(1):19.
100. Rath E, Moschetta A, Haller D. Mitochondrial function - gatekeeper of intestinal epithelial cell homeostasis. *Nat Rev Gastroenterol Hepatol.* 2018;15(8):497-516.
101. Sedda S, Dinallo V, Marafini I, Franzè E, Paoluzi OA, Izzo R, et al. mTOR sustains inflammatory response in celiac disease. *Sci Rep.* 2020;10(1):10798.
102. Larabi A, Barnich N, Nguyen HTT. New insights into the interplay between autophagy, gut microbiota and inflammatory responses in IBD. *Autophagy.* 2020;16(1):38-51.
103. Zhou M, Xu W, Wang J, Yan J, Shi Y, Zhang C, et al. Boosting mTOR-dependent autophagy via upstream TLR4-MyD88-MAPK signalling and downstream NF- κ B pathway quenches intestinal inflammation and oxidative stress injury. *EBioMedicine.* 2018;35:345-60.
104. Khaloian S, Rath E, Hammoudi N, Gleisinger E, Blutke A, Giesbertz P, et al. Mitochondrial impairment drives intestinal stem cell transition into dysfunctional Paneth cells predicting Crohn's disease recurrence. *Gut.* 2020 Nov;69(11):1939-51.
105. Loewith R, Jacinto E, Wullschlegel S, Lorberg A, Crespo JL, Bonenfant D, et al. Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control. *Mol Cell.* 2002;10(3):457-68.
106. Saxton RA, Sabatini DM. mTOR Signaling in Growth, Metabolism, and Disease. *Cell.* 2017;168(6):960-76.
107. González A, Hall MN. Nutrient sensing and TOR signaling in yeast and mammals. *EMBO J.* 2017;36(4):397-408.
108. Carroll B, Korolchuk VI, Sarkar S. Amino acids and autophagy: cross-talk and co-operation to control cellular homeostasis. *Amino Acids.* 2015;47(10):2065-88.
109. Rabanal-Ruiz Y, Otten EG, Korolchuk VI. mTORC1 as the main gateway to autophagy. *Essays Biochem.* 2017;61(6):565-84.
110. Dossou AS, Basu A. The Emerging Roles of mTORC1 in Macromanaging Autophagy. *Cancers (Basel).* 2019 Sep;11(10):1422.
111. Parzych KR, Klionsky DJ. An overview of autophagy: morphology, mechanism, and regulation. *Antioxid Redox Signal.* 2014;20(3):460-73.

112. Kim J, Kundu M, Viollet B, Guan K-L. AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1. *Nat Cell Biol.* 2011;13(2):132–41.
113. Zachari M, Ganley IG. The mammalian ULK1 complex and autophagy initiation. *Essays Biochem.* 2017;61(6):585–96.
114. Simonsen A, Tooze SA. Coordination of membrane events during autophagy by multiple class III PI3-kinase complexes. *J Cell Biol.* 2009;186(6):773–82.
115. Mizushima N. The ATG conjugation systems in autophagy. *Curr Opin Cell Biol.* 2020;63:1–10.
116. Klionsky DJ, Abdel-Aziz AK, Abdelfatah S, Abdellatif M, Abdoli A, Abel S, et al. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition). *Autophagy.* 2021;17(1):1–382.
117. Gatica D, Lahiri V, Klionsky DJ. Cargo recognition and degradation by selective autophagy. *Nat Cell Biol.* 2018;20(3):233–42.
118. Palikaras K, Lionaki E, Tavernarakis N. Mechanisms of mitophagy in cellular homeostasis, physiology and pathology. *Nat Cell Biol.* 2018;20(9):1013–22.
119. Germain K, Kim PK. Pexophagy: A Model for Selective Autophagy. *Int J Mol Sci.* 2020;21(2).
120. Nakatogawa H. Autophagic degradation of the endoplasmic reticulum. *Proc Jpn Acad Ser B Phys Biol Sci.* 2020;96(1):1–9.
121. Picard M, McEwen BS, Epel ES, Sandi C. An energetic view of stress: Focus on mitochondria. *Front Neuroendocrinol.* 2018;49:72–85.
122. Siekevitz P. Powerhouse of the Cell. *Sci Am.* 1957;197(1):131–44.
123. Caruana NJ, Stroud DA. The road to the structure of the mitochondrial respiratory chain supercomplex. *Biochem Soc Trans.* 2020;48(2):621–9.
124. Spinelli JB, Haigis MC. The multifaceted contributions of mitochondria to cellular metabolism. *Nat Cell Biol.* 2018;20(7):745–54.
125. Tait SWG, Green DR. Mitochondria and cell signalling. *J Cell Sci.* 2012;125(Pt 4):807–15.
126. Chan DC. Mitochondrial Dynamics and Its Involvement in Disease. *Annu Rev Pathol.* 2020;15:235–59.
127. Eisner V, Picard M, Hajnóczky G. Mitochondrial dynamics in adaptive and maladaptive cellular stress responses. *Nat Cell Biol.* 2018;20(7):755–65.
128. Lin X, Sun Q, Zhou L, He M, Dong X, Lai M, et al. Colonic epithelial mTORC1 promotes ulcerative colitis through COX-2-mediated Th17 responses. *Mucosal Immunol.* 2018;11(6):1663–73.
129. Khare V, Dammann K, Asboth M, Krnjic A, Jambrich M, Gasche C. Overexpression of PAK1 promotes cell survival in inflammatory bowel diseases and colitis-associated cancer. *Inflamm Bowel Dis.* 2015;21(2):287–96.
130. Hu X, Deng J, Yu T, Chen S, Ge Y, Zhou Z, et al. ATF4 Deficiency Promotes Intestinal Inflammation in Mice by Reducing Uptake of Glutamine and Expression of Antimicrobial Peptides. *Gastroenterology.* 2019;156(4):1098–111.
131. Comincini S, Manai F, Meazza C, Pagani S, Martinelli C, Pasqua N, et al. Identification of Autophagy-Related Genes and Their Regulatory miRNAs Associated with Celiac Disease in Children. *Int J Mol Sci.* 2017;18(2):391.
132. Manai F, Azzalin A, Morandi M, Riccardi V, Zanoletti L, Dei Giudici M, et al. Trehalose Modulates Autophagy Process to Counteract Gliadin Cytotoxicity in an In Vitro Celiac Disease Model. *Cells.* 2019;8(4):348.

133. Boyapati RK, Dorward DA, Tamborska A, Kalla R, Ventham NT, Doherty MK, et al. Mitochondrial DNA Is a Pro-Inflammatory Damage-Associated Molecular Pattern Released During Active IBD. *Inflamm Bowel Dis.* 2018;24(10):2113–22.
134. Shiner M, Redmond AO, Hansen JD. The jejunal mucosa in protein-energy malnutrition. A clinical, histological, and ultrastructural study. *Exp Mol Pathol.* 1973;19(1):61–78.
135. Campos J V, Neto UF, Patricio FR, Wehba J, Carvalho AA, Shiner M. Jejunal mucosa in marasmic children. Clinical, pathological, and fine structural evaluation of the effect of protein-energy malnutrition and environmental contamination. *Am J Clin Nutr.* 1979;32(8):1575–91.
136. Brunser O, Castillo C, Araya M. Fine structure of the small intestinal mucosa in infantile marasmic malnutrition. *Gastroenterology.* 1976;70(4):495–507.
137. Theron JJ, Wittmann W, Prinsloo JG. The fine structure of the jejunum in kwashiorkor. *Exp Mol Pathol.* 1971;14(2):184–99.
138. Brooks SE, Goldon MH, Taylor E. Hepatic ultrastructure in children with protein-energy malnutrition. *West Indian Med J.* 1992;41(4):139–45.
139. Blackburn WR, Vinijchaikul K. The pancreas in kwashiorkor. An electron microscopic study. *Lab Invest.* 1969;20(4):305–18.
140. Srikantia SG, Gopalan C. Role of ferritin in nutritional edema. *J Appl Physiol.* 1959;14:829–33.
141. Deo MG, Ramalingaswami V. Production of periportal fatty infiltration of the liver in the rhesus monkey by a protein-deficient diet. *Lab Invest.* 1960;9:319–29.
142. Follis RHJ. A kwashiorkor-like syndrome observed in monkeys fed maize. *Proc Soc Exp Biol Med.* 1957;96(2):523–8.
143. Lowrey RS, Pond WG, Barnes RH, Krook L, Loosli JK. Influence of caloric level and protein quality on the manifestations of protein deficiency in the young pig. *J Nutr.* 1962;78(2):245–53.
144. Kirsch RE, Brock JF, Saunders SJ. Experimental protein-calorie malnutrition. *Am J Clin Nutr.* 1968;21(8):820–6.
145. Salameh E, Jarbeau M, Morel FB, Zeilani M, Aziz M, Déchelotte P, et al. Modeling undernutrition with enteropathy in mice. *Sci Rep.* 2020;10(1):15581.
146. Genton L, Cani PD, Schrenzel J. Alterations of gut barrier and gut microbiota in food restriction, food deprivation and protein-energy wasting. *Clin Nutr.* 2015;34(3):341–9.
147. Yilmaz OH, Katajisto P, Lamming DW, Gultekin Y, Bauer-Rowe KE, Sengupta S, et al. mTORC1 in the Paneth cell niche couples intestinal stem-cell function to calorie intake. *Nature.* 2012;486(7404):490–5.
148. Mehus AA, Picklo MJS. Brain and Hepatic Mt mRNA Is Reduced in Response to Mild Energy Restriction and n-3 Polyunsaturated Fatty Acid Deficiency in Juvenile Rats. *Nutrients.* 2017;9(10):1145.
149. Jahng JW, Kim JG, Kim HJ, Kim B-T, Kang D-W, Lee J-H. Chronic food restriction in young rats results in depression- and anxiety-like behaviors with decreased expression of serotonin reuptake transporter. *Brain Res.* 2007;1150:100–7.
150. Teodósio NR, Lago ES, Romani SA, Guedes RC. A regional basic diet from northeast Brazil as a dietary model of experimental malnutrition. *Arch Latinoam Nutr.* 1990;40(4):533–47.
151. Whitfield-Cargile CM, Cohen ND, Chapkin RS, Weeks BR, Davidson LA, Goldsby JS, et al. The microbiota-derived metabolite indole decreases mucosal inflammation and injury in a murine model of NSAID enteropathy. *Gut Microbes.* 2016;7(3):246–61.

152. Belmonte L, Coëffier M, Le Pessot F, Miralles-Barrachina O, Hiron M, Leplingard A, et al. Effects of glutamine supplementation on gut barrier, glutathione content and acute phase response in malnourished rats during inflammatory shock. *World J Gastroenterol*. 2007;13(20):2833–40.
153. Eyzaguirre-Velásquez J, Olavarría-Ramírez L, González-Arancibia C, Díaz-Merino C, Ariz R, López S, et al. Protein Malnutrition During Juvenile Age Increases Ileal and Colonic Permeability in Rats. *J Pediatr Gastroenterol Nutr*. 2017;64(5):707–12.
154. Rodríguez P, Darmon N, Chappuis P, Candalh C, Blaton MA, Bouchaud C, et al. Intestinal paracellular permeability during malnutrition in guinea pigs: effect of high dietary zinc. *Gut*. 1996;39(3):416–22.
155. Brown EM, Wlodarska M, Willing BP, Vonaesch P, Han J, Reynolds LA, et al. Diet and specific microbial exposure trigger features of environmental enteropathy in a novel murine model. *Nat Commun*. 2015;6:7806.
156. Sampaio IC, Medeiros PHQS, Rodrigues FAP, Cavalcante PA, Ribeiro SA, Oliveira JS, et al. Impact of acute undernutrition on growth, ileal morphology and nutrient transport in a murine model. *Brazilian J Med Biol Res*. 2016;49(10):e5340.
157. Bartelt LA, Bolick DT, Kolling GL, Roche JK, Zaenker EI, Lara AM, et al. Cryptosporidium Priming Is More Effective than Vaccine for Protection against Cryptosporidiosis in a Murine Protein Malnutrition Model. *PLoS Negl Trop Dis*. 2016;10(7):e0004820.
158. Ueno PM, Oriá RB, Maier EA, Guedes M, de Azevedo OG, Wu D, et al. Alanyl-glutamine promotes intestinal epithelial cell homeostasis in vitro and in a murine model of weanling undernutrition. *Am J Physiol Gastrointest Liver Physiol*. 2011;301(4):G612–22.
159. de Queiroz CAA, Fonseca SGC, Frota PB, Figueiredo IL, Aragão KS, Magalhães CEC, et al. Zinc treatment ameliorates diarrhea and intestinal inflammation in undernourished rats. *BMC Gastroenterol*. 2014;14:136.
160. Lykke M, Hother AL, Hansen CF, Friis H, Mølgaard C, Michaelsen KF, et al. Malnutrition induces gut atrophy and increases hepatic fat infiltration: Studies in a pig model of childhood malnutrition. *Am J Transl Res*. 2013;5(5):543–54.
161. Charbonneau MR, O'Donnell D, Blanton L V, Totten SM, Davis JCC, Barratt MJ, et al. Sialylated Milk Oligosaccharides Promote Microbiota-Dependent Growth in Models of Infant Undernutrition. *Cell*. 2016;164(5):859–71.
162. Costa LB, JohnBull EA, Reeves JT, Sevilleja JE, Freire RS, Hoffman PS, et al. Cryptosporidium-malnutrition interactions: mucosal disruption, cytokines, and TLR signaling in a weaned murine model. *J Parasitol*. 2011;97(6):1113–20.
163. Upadhyay P, Ganguly NK, Mahajan RC, Walia BN. Intestinal uptake of nutrients in normal and malnourished animals infected with *Giardia lamblia*. *Digestion*. 1985;32(4):243–8.
164. Shukla G, Sidhu RK. *Lactobacillus casei* as a probiotic in malnourished *Giardia lamblia*-infected mice: a biochemical and histopathological study. *Can J Microbiol*. 2011;57(2):127–35.
165. Bartelt LA, Roche J, Kolling G, Bolick D, Noronha F, Naylor C, et al. Persistent *G. lamblia* impairs growth in a murine malnutrition model. *J Clin Invest*. 2013;123(6):2672–84.
166. Bolick DT, Chen T, Alves LAO, Tong Y, Wu D, Joyner LT 2nd, et al. Intestinal cell kinase is a novel participant in intestinal cell signaling responses to protein malnutrition. *PLoS One*. 2014;9(9):e106902.
167. Yang Y, Li W, Sun Y, Han F, Hu C-AA, Wu Z. Amino acid deprivation disrupts barrier function and induces protective autophagy in intestinal porcine epithelial cells. *Amino Acids*. 2015;47(10):2177–84.

168. Dutta D, Heo I, Clevers H. Disease Modeling in Stem Cell-Derived 3D Organoid Systems. *Trends Mol Med.* 2017;23(5):393–410.
169. Pearce SC, Al-Jawadi A, Kishida K, Yu S, Hu M, Fritzky LF, et al. Marked differences in tight junction composition and macromolecular permeability among different intestinal cell types. *BMC Biol.* 2018;16(1):19.
170. Zietek T, Giesbertz P, Ewers M, Reichart F, Weinmüller M, Urbauer E, et al. Organoids to Study Intestinal Nutrient Transport, Drug Uptake and Metabolism - Update to the Human Model and Expansion of Applications. *Front Bioeng Biotechnol.* 2020;8:577656.
171. Moore SR, Guedes MM, Costa TB, Vallance J, Maier EA, Betz KJ, et al. Glutamine and alanyl-glutamine promote crypt expansion and mTOR signaling in murine enteroids. *Am J Physiol Gastrointest Liver Physiol.* 2015;308(10):G831-9.
172. Saito Y, Iwatsuki K, Hanyu H, Maruyama N, Aihara E, Tadaishi M, et al. Effect of essential amino acids on enteroids: Methionine deprivation suppresses proliferation and affects differentiation in enteroid stem cells. *Biochem Biophys Res Commun.* 2017;488(1):171–6.

PART I

CLINICAL STUDIES

